Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. - Wikidata - wikimedia - TriplyDB

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

http://www.wikidata.org/entity/Q33978763

about

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards Metabolic communication in tumors: a new layer of immunoregulation for immune evasion Dendritic cell-based vaccine for pancreatic cancer in Japan Distinct Functions of Neutrophil in Cancer and Its Regulation Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy How Neutrophils Shape Adaptive Immune Responses Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Role of immunotherapy for renal cell cancer in 2011 Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses Regulation of tumor metastasis by myeloid-derived suppressor cells Circulating biomarkers in advanced renal cell carcinoma: clinical applications Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences Phenotype, development, and biological function of myeloid-derived suppressor cells Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Coordinated regulation of myeloid cells by tumours Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment.Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling.Immunological deregulation in classic hodgkin lymphoma.Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma.Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer.A simple method for removing low-density granulocytes to purify T lymphocytes from peripheral blood mononuclear cells Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer Pegylated arginase I: a potential therapeutic approach in T-ALL Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.

P2860

Q26744395-1D61189D-1A58-4802-8225-11A16F2F3625 Q26765256-C97F8FCE-A877-4C73-9531-EFB6CC6781F5 Q26768252-28ADC7E9-8281-4425-8DB2-5CC3890BCEDE Q26773228-875C3757-2B0E-48DA-BCBD-1C3F25FDD658 Q26779184-735400BF-0E25-42BB-93DA-EFA67943E378 Q26781286-91F71FED-2F72-493D-B4E2-5674CD3AFA0E Q26798402-6932471A-1233-4019-B637-4D4443A651EE Q26799126-ED50995E-6F7D-4F1A-810F-EF03F67BC42D Q26853453-1DE810A8-BDED-4F9E-A90A-F3A5309F561D Q27001081-7064531C-F160-4EFC-BE54-EDDB9AE9F0DB Q27022125-62D12DC7-D2CF-4EF3-AC7B-B2D03249CB80 Q27023770-98CF9DE7-4C99-46AB-B036-2DBBC9BBFA12 Q27027064-32A34F50-D6E5-42FD-9DA5-3E1962E92B36 Q28079046-7DF7277C-F79F-40BB-B1F1-C2EE6409E2DE Q28080262-4A53620D-FB07-4E0F-898B-90080B83472D Q28294740-8DC634A5-E23E-4C22-86B7-DC0E38E8A5B9 Q28393381-880F9216-BA6F-44AB-8137-57FFC9C4641A Q28393614-DC74F693-0440-4434-A7DA-2116E9FFBC8C Q28395157-6615BCB4-10FA-485A-8D2A-6A327BCCE7AF Q28481476-992A5B39-E7DD-4B3B-A7F0-34968486D447 Q30275254-506C8800-5EBD-41B1-9A50-C96C02760B8E Q30411008-A7119F0B-C5B0-442C-9EB3-AF9D96005848 Q30415763-67D79305-DA5D-4F08-9AAE-50E6D0E087D6 Q30578330-434A9DA2-921E-4EC4-A317-0EF8764B8512 Q33416940-0162F480-518B-4184-8390-3FB3C32E9C30 Q33555406-0A8B6226-F61C-431B-8752-494D80F43DF5 Q33584867-89BA2091-C673-4273-95DC-0DC20ECBA359 Q33606107-C365E34C-E72F-4F9D-8258-94B52EF774B0 Q33772651-E6CBA09B-F6E8-4BD7-A726-36CEDFF310DA Q33778391-A3C4F860-9475-4577-B5BB-99DE9243FBFC Q33792392-DE7E6008-B2B5-4630-B1D5-6224D4138E04 Q33805313-E0E21DED-0101-4872-A907-7D30876BC178 Q33816141-0AEA1836-8F38-4788-927C-93EAECB772F7 Q33816412-A288EEBB-6040-44CB-8188-2AC94111470A Q33876339-5CF81711-7FC1-44BE-9E77-0ED9C9BCC0A4 Q33888808-1F5AEA69-216B-4FAB-BFE0-9B87FF319FB8 Q33944287-3E36B477-7D35-415A-98A4-E622C6FF7491 Q33952083-490FA3C4-F9E7-40DE-9AA2-8E17B6AC3BD1 Q34072679-8709B03F-3FFF-4E60-B57A-863AAB43E12C Q34081723-F7726A02-A8B9-4AEC-B2D5-AC9D3C2FFC38

P2860

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

http://www.wikidata.org/entity/Q33978763

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@ast

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@en

type

label

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@ast

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@en

prefLabel

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@ast

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@en

P1433

Q33978763-3BB9E1DE-628D-4C84-87C7-A069D64CD864

P1476

Q33978763-8D716A20-70BF-45C9-AB1A-28AB0BFD5847

P2093

Q33978763-0C561D0A-5776-4EBC-A376-CF480532308E

Q33978763-3C4D1580-6AC3-4F9F-A4E9-071E64E96239

Q33978763-5AED1622-CBF6-4BB3-A3A9-B89790176B54

Q33978763-64212041-345E-4573-BD23-48935F152835

Q33978763-79ED5DCB-33F0-4248-A86C-AC8DD81D9EBB

Q33978763-85F2011E-0294-4EE3-92AC-FE9585B648FB

Q33978763-862097C1-889C-4A5F-B6A4-955F4126A20C

P2860

Q33978763-06C30D22-9DFF-46F5-9427-EA21813C5A6A

Q33978763-0EB6D113-07AE-4E9A-8561-8386C479BB8D

Q33978763-12A51A5A-E833-43CB-A023-E6C2C5CAFB2F

Q33978763-1AA2A89E-9794-421D-8B9C-E81DCE5E5043

Q33978763-2CEFCD10-A82B-43B5-8C89-5ED88CA8FEEF

Q33978763-3128F682-5DD5-4C89-B81C-3063C65B26CE

Q33978763-31CABB5C-F2E2-4BF9-8A39-C96F6D6E00F9

Q33978763-3674C8E9-6D76-45C7-B176-FCD7F36C5212

Q33978763-4DF827F7-B1BF-4722-AC5E-F84284EDED93

Q33978763-59EAB029-FC77-4607-9197-7248E85ADFFA

P304

Q33978763-8F7CF3B8-CAF5-41BA-AF7A-2ABC1BAC6E98

P31

Q33978763-46D9377D-84D0-482E-B6D1-C44C198CEEEB

P356

Q33978763-5641FB1B-0DF2-42A7-8862-CA179DDB187E

P407

Q33978763-DB2E0CC2-1353-4944-A6C1-07FAB424DF7F

P433

Q33978763-7502477E-891C-471A-AC39-7036BF40FA2F

P478

Q33978763-ACD37738-D3C6-48D9-AA3B-41DF6B243D9E

P577

Q33978763-CA53A723-9EDF-478F-B52A-72328CED8607

P698

Q33978763-907EB261-1141-42A5-95DC-C693F424440B

P932

Q33978763-0CE10035-67E4-4977-9721-4940B2C2997A

P356

0008-5472.CAN-08-1921

P1433

Cancer Research

P1476

Arginase I-producing myeloid-d ...... ion of activated granulocytes.

@en

P2093

Augusto C Ochoa

http://www.w3.org/2001/XMLSchema#string

Claudia Hernandez

http://www.w3.org/2001/XMLSchema#string

Jovanny Zabaleta

http://www.w3.org/2001/XMLSchema#string

Marc S Ernstoff

http://www.w3.org/2001/XMLSchema#string

Michael Atkins

http://www.w3.org/2001/XMLSchema#string

Paulo C Rodriguez

http://www.w3.org/2001/XMLSchema#string

Rosa Sierra

http://www.w3.org/2001/XMLSchema#string

P2860

Gelatinase B functions as regulator and effector in leukocyte biology

Immunosuppressive strategies that are mediated by tumor cells

Neutrophil granules: a library of innate immunity proteins.

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils.

Surface antigen changes during normal neutrophilic development: a critical review.

L-arginine availability regulates T-lymphocyte cell-cycle progression

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Systems biology of neutrophil differentiation and immune response.

P304

1553-1560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-1921

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19201693

http://www.w3.org/2001/XMLSchema#string

P932

2900845

http://www.w3.org/2001/XMLSchema#string